Fagron, Inc. is recalling 120 containers of Nystatin bulk powder (nystatin) used for prescription compounding because the label strength (assay value) is incorrect. The recall affects four different dosage strengths of the bulk powder distributed to pharmacies and distributors across the United States and Canada. This labeling error means medications compounded with this powder could contain the wrong amount of the active ingredient.
The incorrect strength on the label can lead to pharmacy compounding errors, resulting in medications that are either too strong or too weak. This may cause patients to receive an improper dose, which could lead to treatment failure or potential side effects.
You have 2 options:
Rx Only, For Prescription Compounding
Rx Only, For Prescription Compounding
Rx Only, For Prescription Compounding
Rx Only, For Prescription Compounding
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES ยท Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.